Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
BMC Health Services Research|January 8, 2025
Development and usability testing of a multifaceted intervention to reduce low-value injury careMélanie Bérubé, Alexandra Lapierre, Michael Sykes, et al.
Cancer Research|March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathwayJian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
Implementation Science : IS|July 7, 2023
Evaluating the effectiveness of a multifaceted intervention to reduce low-value care in adults hospitalized following trauma: a protocol for a pragmatic cluster randomized controlled trialLynne Moore, Mélanie Bérubé, Amina Belcaid, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
The New England Journal of Medicine|July 15, 2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple MyelomaShaji Kumar, Susanna Jacobus, Adam Cohen, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
BMC Medical Research Methodology|July 4, 2026
Integrating health economics and implementation science: a call to actionLane Meredith, Helen Skouteris, Sarah Alderson, et al.
Frontiers in Oncology|December 19, 2023
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survivalRao Prabhala, William E Pierceall, Mehmet Samur, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneOmar Nadeem, Michelle P Aranha, Robert Redd, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Pageof 11